NO20005618L - Komponenter for behandlingen av kvinnelig seksuell dysfunksjon - Google Patents
Komponenter for behandlingen av kvinnelig seksuell dysfunksjonInfo
- Publication number
- NO20005618L NO20005618L NO20005618A NO20005618A NO20005618L NO 20005618 L NO20005618 L NO 20005618L NO 20005618 A NO20005618 A NO 20005618A NO 20005618 A NO20005618 A NO 20005618A NO 20005618 L NO20005618 L NO 20005618L
- Authority
- NO
- Norway
- Prior art keywords
- agent
- camp
- female
- fsd
- animal
- Prior art date
Links
- 206010057671 Female sexual dysfunction Diseases 0.000 title abstract 6
- 239000003795 chemical substances by application Substances 0.000 abstract 12
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract 7
- 102000003729 Neprilysin Human genes 0.000 abstract 5
- 108090000028 Neprilysin Proteins 0.000 abstract 5
- 210000004392 genitalia Anatomy 0.000 abstract 5
- 230000000694 effects Effects 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 2
- 238000010171 animal model Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 230000017531 blood circulation Effects 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 230000001568 sexual effect Effects 0.000 abstract 2
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000001196 vasorelaxation Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9926437A GB9926437D0 (en) | 1999-11-08 | 1999-11-08 | Pharmaceutical |
| GB0004021A GB0004021D0 (en) | 2000-02-18 | 2000-02-18 | Pharmaceutical |
| GB0013001A GB0013001D0 (en) | 2000-05-26 | 2000-05-26 | Pharmaceutical |
| GB0016563A GB0016563D0 (en) | 2000-07-05 | 2000-07-05 | Pharmaceutical |
| GB0017141A GB0017141D0 (en) | 2000-07-12 | 2000-07-12 | Pharmaceutical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20005618D0 NO20005618D0 (no) | 2000-11-07 |
| NO20005618L true NO20005618L (no) | 2001-05-09 |
Family
ID=27515922
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005661A NO20005661L (no) | 1999-11-08 | 2000-11-07 | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon |
| NO20005618A NO20005618L (no) | 1999-11-08 | 2000-11-07 | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon |
| NO20005662A NO20005662L (no) | 1999-11-08 | 2000-11-07 | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005661A NO20005661L (no) | 1999-11-08 | 2000-11-07 | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20005662A NO20005662L (no) | 1999-11-08 | 2000-11-07 | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6734186B1 (no) |
| EP (5) | EP1097718A1 (no) |
| JP (9) | JP2001247479A (no) |
| KR (7) | KR20010082544A (no) |
| CN (5) | CN1328824A (no) |
| AT (1) | ATE285249T1 (no) |
| AU (6) | AU7140900A (no) |
| BR (3) | BR0005266A (no) |
| CA (4) | CA2323464A1 (no) |
| CO (2) | CO5680109A1 (no) |
| CZ (3) | CZ20004110A3 (no) |
| DE (1) | DE60016877T2 (no) |
| DK (1) | DK1097719T3 (no) |
| EA (3) | EA200001042A3 (no) |
| ES (1) | ES2233297T3 (no) |
| HK (3) | HK1040627A1 (no) |
| HU (4) | HUP0004350A2 (no) |
| IL (4) | IL139456A0 (no) |
| MY (2) | MY140534A (no) |
| NO (3) | NO20005661L (no) |
| NZ (4) | NZ508006A (no) |
| PE (4) | PE20010817A1 (no) |
| PL (3) | PL343753A1 (no) |
| PT (1) | PT1097719E (no) |
| SK (3) | SK16712000A3 (no) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
| DK172900B1 (da) | 1998-12-18 | 1999-09-27 | Per Julius Nielsen | Præparat samt kit til brug ved intraoculære operationer |
| US20050070499A1 (en) * | 1999-11-08 | 2005-03-31 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
| US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| NZ526925A (en) * | 2000-12-15 | 2005-03-24 | Pfizer | Treatment of male sexual dysfunction |
| US6660756B2 (en) | 2001-03-28 | 2003-12-09 | Pfizer Inc. | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| EA006154B1 (ru) | 2001-03-28 | 2005-10-27 | Пфайзер Инк. | N-фенпропилциклопентил-замещенные производные глутарамида в качестве nep ингибиторов при fsad |
| GB0111709D0 (en) * | 2001-05-14 | 2001-07-04 | Pfizer Ltd | Novel pharmaceuticals |
| AR037097A1 (es) | 2001-10-05 | 2004-10-20 | Novartis Ag | Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| US20060106037A1 (en) * | 2003-03-04 | 2006-05-18 | Thomas Bar | Purin-6-one-derivatives |
| ES2737835T3 (es) | 2003-04-23 | 2020-01-16 | Valeritas Inc | Bomba accionada hidráulicamente para la administración de medicamentos de larga duración |
| US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| US7452875B2 (en) | 2003-09-26 | 2008-11-18 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7262184B2 (en) | 2003-09-26 | 2007-08-28 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US7427611B2 (en) | 2003-09-26 | 2008-09-23 | Solvay Pharmaceuticals Gmbh | Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them |
| US20050267072A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction |
| US20050267124A1 (en) * | 2004-05-14 | 2005-12-01 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors |
| WO2005123119A2 (en) * | 2004-06-10 | 2005-12-29 | Catalyst Biosciences, Inc. | Administration of neutral endopeptidase to treat inflammatory bowel disease |
| WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
| ATE412648T1 (de) | 2005-03-21 | 2008-11-15 | Pfizer Ltd | Substituierte triazolderivate als oxytocinantagonisten |
| JP2009532117A (ja) | 2006-03-30 | 2009-09-10 | ヴァレリタス，エルエルシー | マルチカートリッジ式流体投与装置 |
| AU2007256633B2 (en) | 2006-06-06 | 2013-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
| US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| US8650937B2 (en) | 2008-09-19 | 2014-02-18 | Tandem Diabetes Care, Inc. | Solute concentration measurement device and related methods |
| PE20110834A1 (es) | 2008-12-06 | 2011-12-14 | Intra Cellular Therapies Inc | DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1) |
| EA201170773A1 (ru) | 2008-12-06 | 2012-01-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP5813511B2 (ja) | 2008-12-06 | 2015-11-17 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| US20130213393A1 (en) | 2009-12-22 | 2013-08-22 | Evoke Pharma, Inc. | Nasal formulations of metoclopramide |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2011011312A1 (en) | 2009-07-22 | 2011-01-27 | Merck Sharp & Dohme Corp. | Quinolinone pde2 inhibitors |
| EP2724739B1 (en) | 2009-07-30 | 2015-07-01 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| BR112014013650A2 (pt) * | 2011-12-05 | 2017-07-04 | Suda Ltd | "formulações de pulverização oral e seus usos" |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9381297B2 (en) | 2012-06-07 | 2016-07-05 | Tandem Diabetes Care, Inc. | Sealed infusion device with electrical connector port |
| US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
| DK3177627T3 (da) | 2014-08-07 | 2019-10-21 | Intra Cellular Therapies Inc | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| EP3285581B1 (en) | 2015-03-26 | 2021-08-11 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| US10195201B2 (en) | 2015-05-05 | 2019-02-05 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3865484B1 (en) | 2015-07-07 | 2023-11-08 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
| US10492141B2 (en) | 2015-11-17 | 2019-11-26 | Tandem Diabetes Care, Inc. | Methods for reduction of battery usage in ambulatory infusion pumps |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CA3047088A1 (en) | 2016-12-15 | 2018-06-21 | Evoke Pharma, Inc. | Treatment of moderate and severe gastroparesis |
| WO2019152697A1 (en) | 2018-01-31 | 2019-08-08 | Intra-Cellular Therapies, Inc. | Novel uses |
| CN114533740B (zh) * | 2022-02-10 | 2024-04-12 | 广州威生医药科技有限公司 | 一种公猪气味剂组合物及其应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| KR880007441A (ko) * | 1986-12-11 | 1988-08-27 | 알렌 제이.스피겔 | 스피로-치환된 글루타르아미드 이뇨제 |
| US4749717A (en) * | 1987-01-08 | 1988-06-07 | Smithkline Beckman Corporation | Dopamine-beta-hydroxylase inhibitors |
| AU6522590A (en) * | 1989-09-18 | 1991-04-18 | Senetek Plc | Method for inducing vaginal lubrication |
| US5380758A (en) | 1991-03-29 | 1995-01-10 | Brigham And Women's Hospital | S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
| US5612314A (en) | 1995-04-21 | 1997-03-18 | Brigham & Women's Hospital | Nitrosylated neuropeptides |
| DE19541264A1 (de) * | 1995-11-06 | 1997-05-07 | Bayer Ag | Purin-6-on-derivate |
| WO1997020821A1 (en) * | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl derivatives |
| US5798246A (en) | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
| GB9608408D0 (en) * | 1996-04-23 | 1996-06-26 | Adams Michael A | Treatment of erectile dysfunction |
| ATE230403T1 (de) * | 1996-07-23 | 2003-01-15 | Neurogen Corp | Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
| US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
| US20020004529A1 (en) * | 1997-10-20 | 2002-01-10 | Gary W. Neal | Methods, compositions, and kits for enhancing female sexual desire and responsiveness |
| GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US5965718A (en) * | 1997-10-24 | 1999-10-12 | The Scripps Research Institute | Analogs of sarcodictyin and eleutherobin |
| CA2306837C (en) | 1997-10-28 | 2007-05-08 | Asivi, Llc. | Treatment of female sexual dysfunction |
| AUPP010397A0 (en) * | 1997-10-30 | 1997-11-20 | Vaisman, Jakov | Method and composition for treatment of sexual dysfunction |
| IL135462A0 (en) * | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| EP1059926A2 (en) * | 1997-12-18 | 2000-12-20 | SCOTT, Nathan Earl | PROSTAGLANDIN E 2?/F 2$g(a)? COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL |
| CA2339630C (en) | 1998-09-16 | 2006-05-23 | Icos Corporation | Carboline derivatives as cgmp phosphodiesterase inhibitors |
| US6486207B2 (en) * | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US20020169101A1 (en) * | 1999-05-10 | 2002-11-14 | Gonzalez Maria Isabel | Treatment of sexual dysfunction |
| US20020052370A1 (en) * | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
-
2000
- 2000-11-02 IL IL13945600A patent/IL139456A0/xx unknown
- 2000-11-02 IL IL13945700A patent/IL139457A0/xx unknown
- 2000-11-02 IL IL13945400A patent/IL139454A0/xx unknown
- 2000-11-02 IL IL13945500A patent/IL139455A0/xx unknown
- 2000-11-03 EP EP20000309720 patent/EP1097718A1/en not_active Withdrawn
- 2000-11-03 DE DE60016877T patent/DE60016877T2/de not_active Expired - Fee Related
- 2000-11-03 SK SK1671-2000A patent/SK16712000A3/sk unknown
- 2000-11-03 DK DK00309722T patent/DK1097719T3/da active
- 2000-11-03 SK SK1672-2000A patent/SK16722000A3/sk unknown
- 2000-11-03 SK SK1670-2000A patent/SK16702000A3/sk unknown
- 2000-11-03 EP EP20000309719 patent/EP1097707A1/en not_active Withdrawn
- 2000-11-03 PT PT00309722T patent/PT1097719E/pt unknown
- 2000-11-03 ES ES00309722T patent/ES2233297T3/es not_active Expired - Lifetime
- 2000-11-03 EP EP20040020972 patent/EP1481667A1/en not_active Withdrawn
- 2000-11-03 AT AT00309722T patent/ATE285249T1/de not_active IP Right Cessation
- 2000-11-03 EP EP00309718A patent/EP1097706A1/en not_active Withdrawn
- 2000-11-03 EP EP00309722A patent/EP1097719B1/en not_active Expired - Lifetime
- 2000-11-06 MY MYPI20005205A patent/MY140534A/en unknown
- 2000-11-06 CZ CZ20004110A patent/CZ20004110A3/cs unknown
- 2000-11-06 CZ CZ20004106A patent/CZ20004106A3/cs unknown
- 2000-11-06 AU AU71409/00A patent/AU7140900A/en not_active Abandoned
- 2000-11-06 AU AU71411/00A patent/AU781186B2/en not_active Ceased
- 2000-11-06 MY MYPI20005202A patent/MY141651A/en unknown
- 2000-11-06 CZ CZ20004107A patent/CZ20004107A3/cs unknown
- 2000-11-06 AU AU71408/00A patent/AU781403B2/en not_active Ceased
- 2000-11-06 AU AU71407/00A patent/AU781400B2/en not_active Ceased
- 2000-11-07 CN CN00137670A patent/CN1328824A/zh active Pending
- 2000-11-07 KR KR1020000065761A patent/KR20010082544A/ko not_active Application Discontinuation
- 2000-11-07 KR KR1020000065740A patent/KR20010051481A/ko not_active Application Discontinuation
- 2000-11-07 NZ NZ508006A patent/NZ508006A/en unknown
- 2000-11-07 NO NO20005661A patent/NO20005661L/no not_active Application Discontinuation
- 2000-11-07 NZ NZ508011A patent/NZ508011A/en unknown
- 2000-11-07 NO NO20005618A patent/NO20005618L/no not_active Application Discontinuation
- 2000-11-07 CA CA002323464A patent/CA2323464A1/en not_active Abandoned
- 2000-11-07 HU HU0004350A patent/HUP0004350A2/hu unknown
- 2000-11-07 NZ NZ508007A patent/NZ508007A/en unknown
- 2000-11-07 NZ NZ508012A patent/NZ508012A/en unknown
- 2000-11-07 KR KR1020000065863A patent/KR20010082545A/ko not_active Application Discontinuation
- 2000-11-07 CN CNA2004100859558A patent/CN1636597A/zh active Pending
- 2000-11-07 CO CO00084521A patent/CO5680109A1/es unknown
- 2000-11-07 CO CO00084519A patent/CO5680108A1/es unknown
- 2000-11-07 HU HU0004348A patent/HUP0004348A2/hu not_active Application Discontinuation
- 2000-11-07 HU HU0004347A patent/HUP0004347A2/hu not_active Application Discontinuation
- 2000-11-07 PE PE2000001185A patent/PE20010817A1/es not_active Application Discontinuation
- 2000-11-07 PE PE2000001187A patent/PE20010926A1/es not_active Application Discontinuation
- 2000-11-07 CA CA002323183A patent/CA2323183A1/en not_active Abandoned
- 2000-11-07 CN CNA2004100713908A patent/CN1575816A/zh active Pending
- 2000-11-07 HU HU0004349A patent/HUP0004349A2/hu active IP Right Revival
- 2000-11-07 CA CA002323191A patent/CA2323191A1/en not_active Abandoned
- 2000-11-07 NO NO20005662A patent/NO20005662L/no unknown
- 2000-11-07 CN CN00137671A patent/CN1322526A/zh active Pending
- 2000-11-07 PE PE2000001188A patent/PE20010925A1/es not_active Application Discontinuation
- 2000-11-07 PE PE2000001186A patent/PE20010924A1/es not_active Application Discontinuation
- 2000-11-07 KR KR1020000065868A patent/KR20010086267A/ko not_active Application Discontinuation
- 2000-11-07 CA CA002324484A patent/CA2324484A1/en not_active Abandoned
- 2000-11-07 BR BR0005266-3A patent/BR0005266A/pt not_active IP Right Cessation
- 2000-11-07 CN CN00137665A patent/CN1320426A/zh active Pending
- 2000-11-08 PL PL00343753A patent/PL343753A1/xx unknown
- 2000-11-08 EA EA200001042A patent/EA200001042A3/ru unknown
- 2000-11-08 PL PL00343754A patent/PL343754A1/xx unknown
- 2000-11-08 JP JP2000339957A patent/JP2001247479A/ja active Pending
- 2000-11-08 BR BR0005299-0A patent/BR0005299A/pt not_active IP Right Cessation
- 2000-11-08 EA EA200001044A patent/EA006242B1/ru not_active IP Right Cessation
- 2000-11-08 US US09/708,392 patent/US6734186B1/en not_active Expired - Fee Related
- 2000-11-08 EA EA200001043A patent/EA006254B1/ru active IP Right Revival
- 2000-11-08 BR BR0005276-0A patent/BR0005276A/pt not_active Application Discontinuation
- 2000-11-08 JP JP2000339853A patent/JP2001213802A/ja active Pending
- 2000-11-08 JP JP2000339905A patent/JP2001206855A/ja active Pending
- 2000-11-08 JP JP2000339949A patent/JP2001247478A/ja active Pending
- 2000-11-08 PL PL00343755A patent/PL343755A1/xx unknown
-
2002
- 2002-03-22 HK HK02102197.5A patent/HK1040627A1/zh unknown
- 2002-03-22 HK HK02102195.7A patent/HK1040626A1/zh unknown
- 2002-05-04 HK HK02103406.0A patent/HK1041646A1/zh unknown
-
2004
- 2004-07-01 KR KR1020040050972A patent/KR20040074022A/ko not_active Application Discontinuation
- 2004-07-01 KR KR1020040050971A patent/KR20040074021A/ko not_active Application Discontinuation
- 2004-07-01 KR KR1020040050973A patent/KR20040074023A/ko not_active Application Discontinuation
- 2004-09-15 JP JP2004267669A patent/JP2005021167A/ja not_active Abandoned
- 2004-09-15 JP JP2004268608A patent/JP2005013237A/ja active Pending
- 2004-09-16 JP JP2004269732A patent/JP2005070055A/ja active Pending
- 2004-09-16 JP JP2004269807A patent/JP2005043377A/ja active Pending
-
2005
- 2005-05-18 AU AU2005202166A patent/AU2005202166A1/en not_active Abandoned
- 2005-06-23 AU AU2005202750A patent/AU2005202750A1/en not_active Withdrawn
- 2005-08-11 JP JP2005233224A patent/JP2005350482A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20005618D0 (no) | Komponenter for behandlingen av kvinnelig seksuell dysfunksjon | |
| Korba | In vitro evaluation of combination therapies against hepatitis B virus replication | |
| HUP0301020A2 (hu) | Konformációs betegségek korai diagnosztikája | |
| ATE297723T1 (de) | Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum | |
| DE69943266D1 (de) | Arzneimittel zur behandlung von hiv-infizierten säugetieren | |
| EP1744162A4 (en) | Cancer diagnosis and treatment using an anti-ROBO1 antibody | |
| ATE529743T1 (de) | Verfahren und kits zur tumorigenizitätsdiagnose | |
| Auletta et al. | Estrogen-induced luteolysis in the rhesus monkey: reversal with indomethacin | |
| Brass et al. | Effect of E-series prostaglandins on cyclic AMP-dependent and-independent hormone-stimulated glycogenolysis in hepatocytes | |
| ATE177942T1 (de) | Lösung, die igf-1 enthält | |
| EP1937251A2 (en) | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor | |
| Chan et al. | Amantadine's viral kinetics in chronic hepatitis C infection | |
| Ma et al. | Straightforward and effective synthesis of γ-aminobutyric acid transporter subtype 2-selective acyl-substituted azaspiro [4.5] decanes | |
| CY1108468T1 (el) | Διαγνωση νεφρικων νοσων στον ανθρωπο | |
| JP2004517046A5 (no) | ||
| BR9915820A (pt) | Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação | |
| Kasai et al. | Peptide leukotriene antagonistic activity of AS-35, a new antiallergic drug | |
| Jaffe et al. | Viosterol treatment in experimental hyperparathyroidism. | |
| UA40025A (uk) | Спосіб оцінки адаптаційно-резервних можливостей фето-плацентарного комплексу | |
| Pilawski et al. | Treatment of mixed inflammations of vagina by means of Gyno-Pevaryl preparation | |
| IT1291307B1 (it) | Composizione farmaceutica atta al trattamento delle patologie neurodegenerative | |
| UA64212A (en) | Method for treating urogenital trichomoniasis in women | |
| JPH0586370B2 (no) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |